½ÃÀ庸°í¼­
»óǰÄÚµå
1601055

Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : À¯Çü, ÀûÀÀÁõ, ºÐ¸®¿ø, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Mesenchymal Stem Cells Market by Type (Allogeneic, Autologous), Indication (Bone & Cartilage Repair, Cancer, Cardiovascular Disease), Source of Isolation, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Áß°£¿± Áٱ⼼Æ÷ ½ÃÀåÀº 2023³â¿¡ 35¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³â¿¡´Â 39¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 13.63%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 85¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áß°£¿±Áٱ⼼Æ÷(MSCs)´Â »À, ¿¬°ñ, Áö¹æÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ¼¼Æ÷Çü¿¡ ºÐÈ­ÇÒ ¼ö ÀÖ´Â ´Ù´É¼º°£Áú¼¼Æ÷ÀÔ´Ï´Ù. Àç»ýÀÇ·á MSC ¹üÀ§´Â Á¶Á÷°øÇÐ, ÀÚ°¡¸é¿ªÁúȯ Ä¡·á, ¸é¿ª ¹ÝÀÀ Á¶Àý MSC ¿ªÇÒ ÀáÀçÀûÀÎ ¿ëµµ¿¡ »ó¡µÇµµ·Ï(µíÀÌ), ±¤´ëÇÕ´Ï´Ù. ÁÖ¿ä ¿ëµµ·Î¼­´Â ½ÉÀåÇ÷°ü, Á¤Çü¿Ü°ú, ½Å°æÁúȯ¿¡ ´ëÇÑ Àç»ý Ä¡·á¸¦ µé ¼ö ÀÖ½À´Ï´Ù. Á¦¾à, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, ÇコÄɾîµîÀÇ »ê¾÷ÀÌ, MSC ±â¼ú ÁÖ¿ä ÃÖÁ¾ »ç¿ë ºÐ¾ßÀÔ´Ï´Ù. MSC Çʿ伺Àº ¸¸¼ºÁúȯ Áõ°¡³ª Àα¸ °í·ÉÈ­¿¡ Á÷¸éÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ¼­ °­Á¶µÇ°í ÀÖ¾î ½Å±Ô MSC ±â¹Ý Á¦Ç°¿¡ ´ëÇÑ ¿¬±¸³ª ÅõÀÚ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº Áٱ⼼Æ÷ Ä¡·á ±â¼úÀû Áøº¸, ¿¬±¸ ÀÚ±Ý Áõ°¡, Àç»ýÀǷḦ Áö¿øÇÏ´Â Á¤ºÎ À¯¸®ÇÑ ±ÔÁ¦¿¡ ÀÇÇØ¼­ Å©°Ô Á¿ìµË´Ï´Ù. Çаè¿Í ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷°úÀÇ °øµ¿ ¿¬±¸ Áõ°¡´Â ȹ±âÀûÀÎ Ä¡·á¹ý °¡´É¼ºÀ» ÇÑÃþ ´õ µÎµå·¯Áö°Ô Çϰí ÀÖ½À´Ï´Ù. ±×·¸Áö¸¸, ¾ö°ÝÇÑ ±ÔÁ¦±â°ü ½ÂÀÎ, MSC¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ý °íºñ¿ë, À±¸®Àû ¿ì·Á, Áٱ⼼Æ÷ ºÐÈ­¡¤Áõ½Ä ±â¼úÀû °ï¶õÀ̶ó°í ÇÏ´Â °úÁ¦°¡, ½ÃÀå ÁøÀüÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ ÀÓ»ó °á°ú³ª È®À强 ¹®Á¦°¡, »õ·Î¿î ÇãµéÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å ÁÖ¿ä ºÐ¾ß¿¡´Â Áٱ⼼Æ÷ È¿·ÂÀ̳ª Àü´Þ ¸ÞÄ¿´ÏÁò °­È­, È®Àå °¡´ÉÇÑ Á¦Á¶ °øÁ¤ °³¹ß, ½Ç½Ã°£ »ý¸®ÇÐÀû ¸ð´ÏÅ͸µÀ» À§ÇÑ Ç÷§Æû ±¸ÃàµîÀÌ Æ÷ÇԵ˴ϴÙ. MSC ½ÃÀåÀÌ ¹ßÀüÇÏ´Â °Í¿¡ µû¶ó, ¿¬±¸°³¹ß¿¡ÀÇ Àü·«Àû ÅõÀÚ, ±ÔÁ¦ ±¸Á¶¿¡ÀÇ ÁذŠÁß½Ã, ±â¼ú °øÀ¯À» À§ÇÑ ÆÄÆ®³Ê½Ê È®¸³ÀÌ, Áö¼ÓÀû ¼ºÀå À§ÇØ(¶§¹®¿¡) Áß¿äÇÏ°Ô µÈ´Ù°í »ý°¢µË´Ï´Ù. ÀüüÀûÀ¸·Î, MSC´Â º¹ÀâÇÑ ÀÓ»ó, ±ÔÁ¦, ½ÃÀå ±¸µµ¸¦ Àß ±Øº¹ÇÒ ¼ö ÀÖ´Â »ç¶÷¿¡°Ô À־´Â ´«ºÎ½Ç °¡´É¼ºÀ» ¼û±ä, À¯¸ÁÇϱâ´Â ÇÏÁö¸¸ °úÁ¦µµ ¸¹Àº Àç»ýÀÇ·á ÇÁ·ÐƼ¾îÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 35¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 39¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 85¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 13.63%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³

Áß°£¿± Áٱ⼼Æ÷ ½ÃÀåÀº ¼ö¿ä ¹× °ø±Þ ´ÙÀ̳ª¹ÍÇÑ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ¼­ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐ ÁøÈ­¸¦ ÀÌÇØÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû °áÁ¤ Á¤Ä¡È­, ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº Á¤Ä¡Àû, Áö¿ª ¸ñÇ¥, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °Ç³Ê°¡´Â ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖ¾î ¶ÇÇÑ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Áß°£¿±Áٱ⼼Æ÷¿¡ ±Ù°ÅÇÑ ¿¬±¸ ¼ºÀå
    • °í·ÉÀÚ Àα¸ Áõ°¡¿Í ¸¸¼ºÁúȯ Áõ°¡
    • °è¼Ó ÁøÈ­ÇÏ´Â Áٱ⼼Æ÷ Ä¡·á »óȲ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Áٱ⼼Æ÷ Ä¡·á Ç¥ÁØÈ­¿Í ±ÔÁ¦ °á¿©
  • ½ÃÀå ±âȸ
    • Áß°£¿± Áٱ⼼Æ÷ »õ·Î¿î ÀÀ¿ë¿¹
    • Áß°£¿± Áٱ⼼Æ÷ Á¦Ç° °øµ¿ ¿¬±¸³ª ÆÄÆ®³Ê½Ê È®´ë, Ä¡·á Çõ½Å ÁøÀü
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
    • Àΰ£ Áß°£¿± Áٱ⼼Æ÷ Ä¡·á¿¡ °ü·ÃµÈ À±¸®¡¤¾ÈÀü¼º ¹®Á¦

Porter's Five Forces : Áß°£¿± Áٱ⼼Æ÷ ½ÃÀåÀ» ¾È³»ÇÏ´Â Àü·« Åø

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå ±¸µµ °æÀï ±¸µµ¸¦ ÀÌÇØÇϱâ À§ÇÑ Áß¿ä ÅøÀÔ´Ï´Ù. Porter's Five Forces¡¤ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ °æÀï·ÂÀ» Æò°¡ÇØ, Àü·«Àû ±âȸ¸¦ ã±â À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇØ, ½Å±Ô »ç¾÷ ¼öÀͼºÀ» ÆÇ´ÜÇϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû¿¡ ÀÇÇØ ±â¾÷Àº ÀÚ»ç °­Á¡À» »ì·Á, ¾àÁ¡¿¡ ´ëÃ³ÇØ, ÀáÀçÀûÀÎ °úÁ¦¸¦ ȸÇÇÇÒ ¼ö À־´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå ¿ÜºÎ·ÎºÎÅÍ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ãȯ°æ ¿äÀÎÀº Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå ½ÇÀû ¿ªÇÐÀ» Çü¼ºÇϴµ¥ À־ ¸Å¿ì Áß¿ä ¿ªÇÒÀ» ¿Ï¼öÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» ¾È³»Çϱâ À§Çؼ­ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ´Â °ÍÀ¸·Î, ±â¾÷Àº ÀáÀçÀûÀÎ ¸®½ºÅ©¿Í ±âȸ¸¦ º¸´Ù ÁÁ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®¿¡ ÀÇÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿Çâ º¯È­¸¦ ¿¹ÃøÇØ, ¾ÕÀ» ¿¹ÃøÇÑ Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ½Ç½ÃÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®¿¡ ÀÇÇØ º¥´õ ½ÇÀûÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·üµîÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ´Â °ÍÀ¸·Î, °æÀï»ó Æ÷Áö¼Å´×À» ºÐ¸íÈ÷ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®¿¡ ÀÇÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀÌ ¹àÇôÁ®, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ»ç ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ½Ç½ÃÇϱâ À§Çؼ­ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå º¥´õ ÆÛÆ÷¸Õ½º Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡Çϱâ À§ÇÑ Áß¿ä ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¿¡ ÀÇÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¿¡ ±Ù°ÅÇØ Æò°¡ÇÏ´Â °ÍÀ¸·Î, ¸ñÇ¥¿¡ µû¸¥ ÃæºÐÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç°áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. 4°³ »óÇÑÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇØ, »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥·Î ÃÖÀûÀÎ ÆÄÆ®³Ê³ª ¼Ö·ç¼ÇÀ» ƯÁ¤Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

º» º¸°í¼­´Â ÁÖ¿ä ÁÖ¸ñ ºÐ¾ß¸¦ ¸Á¶óÇÑ Á¾ÇÕÀû½ÃÀå ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù :

1.½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ »ó¼¼ÇÑ ¸®ºä.

2.½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå ¼ºÀå ±âȸ¸¦ ƯÁ¤ÇØ, ±âÁ¸ ºÐ¾ß È®´ë °¡´É¼ºÀ» Æò°¡ÇØ, ÇâÈÄ ¼ºÀåÀ» ÇâÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3.½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° ¹ß¸Å, ¹Ì°³Ã´ Áö¿ª, ¾÷°è ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4.°æÀï Æò°¡¿Í Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÇÏ°Ô ºÐ¼®ÇÏ°í ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦±â°ü ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ ±â¼ú Áøº¸µîÀ» °ËÁõ ÇÕ´Ï´Ù.

5.Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÑ´Ù°í ±â´ëµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» ÇÏÀ̶óÀÌÆ® Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ´ÙÀ½ ÀÇ»ç°áÁ¤ ÇÒ ¼ö ÀÖµµ·Ï, Áß¿ä Áú¹®¿¡µµ ´äÇϰí ÀÖ½À´Ï´Ù :

1.ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2.ÃÖ°í ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµò°¡?

3.½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ ¿µÇâÀ̶õ?

4.ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå Âü¿©¡¤Ã¶Åð Àü·« ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : À¯Çüº°

  • µ¿Á¾ À̰è
  • ÀÚ°¡ À̽Ä

Á¦7Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : ÀûÀÀÁõº°

  • »À ¹× ¿¬°ñ ¼öº¹
  • ¾Ï
  • ½ÉÇ÷°ü Áúȯ
  • ÀÌ½ÄÆí´ë ¼÷ÁÖ Àå¾Ö
  • ¿°Áõ¼º ¹× ¸é¿ª Áúȯ
  • °£ Áúȯ

Á¦8Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : °Ý¸®¿øº°

  • Áö¹æÁ¶Á÷
  • °ñ¼ö
  • Á¦´ëÇ÷
  • ³­°ü
  • ÅÂ¾Æ °£
  • Æó
  • ¸»ÃÊÇ÷

Á¦9Àå Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå : ¿ëµµº°

  • Áúȯ ¸ðµ¨
  • Drug Development & Discovery
  • Áٱ⼼Æ÷ ÀºÇà
  • Á¶Á÷°øÇÐ
  • µ¶¼ºÇÐ ¿¬±¸

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Áß°£¿± Áٱ⼼Æ÷ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • PromoCell GmbH
  • Globus Medical
  • Pluri Biotech Ltd.
  • ScienCell Research Laboratories, Inc.
  • Stemedica Cell Technologies, Inc.
  • Cyagen Biosciences, Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Stemcell Technologies Inc.
  • AMS Biotechnology
  • Mesoblast Limited
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Genlantis, Inc.
  • Celprogen, Inc.
  • Takeda Pharmaceutical Company Limited
  • Athersys, Inc.
  • R&D Systems, Inc.
  • Smith & Nephew PLC
  • Cytori Therapeutics Inc.
  • Axol Biosciences Ltd.
  • Neuromics
  • Vericel Corporation
  • Hope Biosciences, LLC
  • Cell Applications, Inc.
  • Astellas Pharma Inc.
LSH 24.12.06

The Mesenchymal Stem Cells Market was valued at USD 3.51 billion in 2023, expected to reach USD 3.98 billion in 2024, and is projected to grow at a CAGR of 13.63%, to USD 8.59 billion by 2030.

Mesenchymal Stem Cells (MSCs) are multipotent stromal cells capable of differentiating into various cell types, including bone, cartilage, and fat. The scope of MSCs in regenerative medicine is vast, epitomized by their potential use in tissue engineering, the treatment of autoimmune diseases, and their role in modulating immune responses. Key applications include regenerative treatments for cardiovascular, orthopedic, and neurological disorders. Industries such as pharmaceuticals, biotechnology, and healthcare are primary end-use sectors for MSC technologies. The necessity of MSCs is underscored by the growing demand for innovative therapies in the face of rising chronic diseases and an aging population, fueling research and investments in novel MSC-based products. Market growth is significantly influenced by technological advancements in stem cell therapy, increased funding for research, and favorable government regulations supporting regenerative medicine, thereby creating opportunities for new market entrants and existing players to expand their offerings. The rise in collaborations between academia and biotech firms further accentuates the potential for groundbreaking therapies. However, challenges such as stringent regulatory approvals, high costs of MSC-based therapies, ethical concerns, and technical difficulties in stem cell differentiation and proliferation can impede market progress. Moreover, the varied clinical outcomes and scalability issues pose additional hurdles. Key areas of innovation include enhancing MSC potency and delivery mechanisms, developing scalable manufacturing processes, and creating platforms for real-time physiological monitoring. As the MSC market evolves, strategic investments in R&D, emphasis on compliance with regulatory frameworks, and the establishment of partnerships for technology sharing will be critical for sustained growth. Overall, MSCs present a promising yet challenging frontier in regenerative medicine, with remarkable potential for those capable of navigating the complex clinical, regulatory, and market landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 3.51 billion
Estimated Year [2024] USD 3.98 billion
Forecast Year [2030] USD 8.59 billion
CAGR (%) 13.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Mesenchymal Stem Cells Market

The Mesenchymal Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growth in Mesenchymal Stem Cell-Based Research
    • Rising Geriatric Population Coupled with Growth in Chronic Diseases
    • Continuously Evolving Landscape of Stem Cell Therapies
  • Market Restraints
    • Lack of Standardized and Regulated Delivery of Stem Cell Therapy
  • Market Opportunities
    • Emerging Applications of Mesenchymal Stem Cells
    • Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
  • Market Challenges
    • Ethical & Safety Issues Associated with Human MSC Therapy

Porter's Five Forces: A Strategic Tool for Navigating the Mesenchymal Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Mesenchymal Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Mesenchymal Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Mesenchymal Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Mesenchymal Stem Cells Market

A detailed market share analysis in the Mesenchymal Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Mesenchymal Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Mesenchymal Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Mesenchymal Stem Cells Market, highlighting leading vendors and their innovative profiles. These include PromoCell GmbH, Globus Medical, Pluri Biotech Ltd., ScienCell Research Laboratories, Inc., Stemedica Cell Technologies, Inc., Cyagen Biosciences, Inc., BrainStorm Cell Therapeutics Inc., Stemcell Technologies Inc., AMS Biotechnology, Mesoblast Limited, Thermo Fisher Scientific, Inc., Lonza Group AG, Merck KGaA, Genlantis, Inc., Celprogen, Inc., Takeda Pharmaceutical Company Limited, Athersys, Inc., R&D Systems, Inc., Smith & Nephew PLC, Cytori Therapeutics Inc., Axol Biosciences Ltd., Neuromics, Vericel Corporation, Hope Biosciences, LLC, Cell Applications, Inc., and Astellas Pharma Inc..

Market Segmentation & Coverage

This research report categorizes the Mesenchymal Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Allogeneic and Autologous.
  • Based on Indication, market is studied across Bone & Cartilage Repair, Cancer, Cardiovascular Disease, GvHD, Inflammatory & Immunological Disease, and Liver Diseases.
  • Based on Source of Isolation, market is studied across Adipose Tissues, Bone Marrow, Cord Blood, Fallopian Tube, Fetal Liver, Lung, and Peripheral Blood.
  • Based on Application, market is studied across Disease Modeling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, and Toxicology Studies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growth in Mesenchymal Stem Cell-Based Research
      • 5.1.1.2. Rising Geriatric Population Coupled with Growth in Chronic Diseases
      • 5.1.1.3. Continuously Evolving Landscape of Stem Cell Therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Standardized and Regulated Delivery of Stem Cell Therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging Applications of Mesenchymal Stem Cells
      • 5.1.3.2. Growing Collaborations and Partnerships and Advancing Therapeutic Innovations of Mesenchymal Stem Cell Products
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical & Safety Issues Associated with Human MSC Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Immunological safety and personalized nature of autologous MSCs to make them beneficial for long-term treatments
    • 5.2.2. Indication: Substantial research and development activities on MSCs for the treatment of CVDs
    • 5.2.3. Source of Isolation: High cell yield and established therapeutic use of bone-marrow derived MSC
    • 5.2.4. Application: Benefits of MSCs in disease modeling and drug discovery due to their ability to mimic human diseases and test drug efficacy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Mesenchymal Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Allogeneic
  • 6.3. Autologous

7. Mesenchymal Stem Cells Market, by Indication

  • 7.1. Introduction
  • 7.2. Bone & Cartilage Repair
  • 7.3. Cancer
  • 7.4. Cardiovascular Disease
  • 7.5. GvHD
  • 7.6. Inflammatory & Immunological Disease
  • 7.7. Liver Diseases

8. Mesenchymal Stem Cells Market, by Source of Isolation

  • 8.1. Introduction
  • 8.2. Adipose Tissues
  • 8.3. Bone Marrow
  • 8.4. Cord Blood
  • 8.5. Fallopian Tube
  • 8.6. Fetal Liver
  • 8.7. Lung
  • 8.8. Peripheral Blood

9. Mesenchymal Stem Cells Market, by Application

  • 9.1. Introduction
  • 9.2. Disease Modeling
  • 9.3. Drug Development & Discovery
  • 9.4. Stem Cell Banking
  • 9.5. Tissue Engineering
  • 9.6. Toxicology Studies

10. Americas Mesenchymal Stem Cells Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Mesenchymal Stem Cells Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Mesenchymal Stem Cells Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cellcolabs Announces Partnership With REPROCELL for Research And GMP Grade MSC And MSC Derivatives
    • 13.3.2. PromoCell Launches PromoExQ MSC Growth Medium XF for GMP-Compliant Isolation and Expansion of Mesenchymal Stem Cells
    • 13.3.3. Pluristyx and Stemmatters Announce Partnership to Develop and Manufacture iPSC-derived MSC Banks

Companies Mentioned

  • 1. PromoCell GmbH
  • 2. Globus Medical
  • 3. Pluri Biotech Ltd.
  • 4. ScienCell Research Laboratories, Inc.
  • 5. Stemedica Cell Technologies, Inc.
  • 6. Cyagen Biosciences, Inc.
  • 7. BrainStorm Cell Therapeutics Inc.
  • 8. Stemcell Technologies Inc.
  • 9. AMS Biotechnology
  • 10. Mesoblast Limited
  • 11. Thermo Fisher Scientific, Inc.
  • 12. Lonza Group AG
  • 13. Merck KGaA
  • 14. Genlantis, Inc.
  • 15. Celprogen, Inc.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Athersys, Inc.
  • 18. R&D Systems, Inc.
  • 19. Smith & Nephew PLC
  • 20. Cytori Therapeutics Inc.
  • 21. Axol Biosciences Ltd.
  • 22. Neuromics
  • 23. Vericel Corporation
  • 24. Hope Biosciences, LLC
  • 25. Cell Applications, Inc.
  • 26. Astellas Pharma Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦